Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
126 hedge funds and large institutions have $298M invested in Intra-Cellular Therapies Inc. in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 35 reducing their positions, and 25 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 35
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
0% more funds holding
Funds holding: 126 → 126 (0)
40% less capital invested
Capital invested by funds: $498M → $298M (-$200M)
41% less call options, than puts
Call options by funds: $15.4M | Put options by funds: $26.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$16M |
| 2 |
Millennium Management
New York
|
+$10.6M |
| 3 |
ClearBridge Investments
New York
|
+$7.53M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.37M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.98M |
| 3 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$7.79M |
| 4 |
CCI
Columbus Circle Investors
|
-$6.93M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.61M |
ITCI Hedge Fund Activity: Q3 2019 in Review
126 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2019, worth a combined $298M — down 40% from $498M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ITCI positions and 25 closed out — a net gain of 1 holder — while 42 added to existing stakes and 35 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $16M. The largest seller was Fidelity Investments, cutting an estimated $20.5M.
- 126 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $298M of Intra-Cellular Therapies Inc. stock for Q3 2019, down 40% quarter-over-quarter.
- 26 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2019 and 25 closed out, a net change of +1 holder.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2019 was Wasatch Advisors, an estimated $16M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2019 was Fidelity Investments, an estimated $20.5M sold.
Based on aggregated 13F filings for Q3 2019.